Preferred Label : toripalimab;

UNII : 8JXN261VVA;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
toripalimab
toripalimab
Cisplatin/Gemcitabine/Toripalimab Regimen
drug approval
europe
antineoplastic combined chemotherapy protocols
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors
toripalimab
adult
Nasopharyngeal Carcinoma
neoplasm recurrence, local
Recurrent Nasopharyngeal Carcinoma
Esophageal Squamous Cell Carcinoma
cisplatin
paclitaxel
Gemcitabine
Unresectable Esophageal Squamous Cell Carcinoma
Recurrent Esophageal Squamous Cell Carcinoma
Metastatic Esophageal Squamous Cell Carcinoma
Advanced Esophageal Squamous Cell Carcinoma
infusions, intravenous
product surveillance, postmarketing
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
drug interactions
pregnancy
breast feeding
programmed cell death 1 receptor

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.